Waitlist Outcomes for Patients Relisted Following Failed Donation After Cardiac Death Liver Transplant: Implications for Awarding Model for End-Stage Liver Disease Exception Scores

被引:7
|
作者
Croome, K. P. [1 ]
Lee, D. D. [1 ]
Nguyen, J. H. [1 ]
Keaveny, A. P. [1 ]
Taner, C. B. [1 ]
机构
[1] Mayo Clin Florida, Dept Transplant, Jacksonville, FL 32224 USA
关键词
ISCHEMIC CHOLANGIOPATHY; BILIARY COMPLICATIONS; CIRCULATORY DEATH; DONORS; RECIPIENTS; RATES; SURVIVAL; GRAFTS; IMPACT;
D O I
10.1111/ajt.14383
中图分类号
R61 [外科手术学];
学科分类号
摘要
Understanding of outcomes for patients relisted for ischemic cholangiopathy following a donation after cardiac death (DCD) liver transplant (LT) will help standardization of a Model for End-Stage Liver Disease exception scheme for retransplantation. Early relisting (E-RL) for DCD graft failure caused by primary nonfunction (PNF) or hepatic artery thrombosis (HAT) was defined as relisting <= 14 days after DCD LT, and late relisting (L-RL) due to biliary complications was defined as relisting 14 days to 3 years after DCD LT. Of 3908 DCD LTs performed nationally between 2002 and 2016, 540 (13.8%) patients were relisted within 3 years of transplant (168 [4.3%] in the E-RL group, 372 [9.5%] in the L-RL group). The ERL and L-RL groups had waitlist mortality rates of 15.4% and 10.5%, respectively, at 3 mo and 16.1% and 14.3%, respectively, at 1 year. Waitlist mortality in the L-RL group was higher than mortality and delisted rates for patients with exception points for both hepatocellular carcinoma (HCC) and hepatopulmonary syndrome (HPS) at 3-to 12-mo time points (p < 0.001). Waitlist outcomes differed in patients with early DCD graft failure caused by PNF or HAT compared with those with late DCD graft failure attributed to biliary complications. In L-RL, higher rates of waitlist mortality were noted compared with patients listed with exception points for HCC or HPS.
引用
收藏
页码:2420 / 2427
页数:8
相关论文
共 50 条
  • [41] The Effect of Acuity Circles on Deceased Donor Transplant and Offer Rates Across Model for End-Stage Liver Disease Scores and Exception Statuses
    Wey, Andrew
    Noreen, Samantha
    Gentry, Sommer
    Cafarella, Matt
    Trotter, James
    Salkowski, Nicholas
    Segev, Dorry
    Israni, Ajay
    Kasiske, Bertram
    Hirose, Ryutaro
    Snyder, Jon
    LIVER TRANSPLANTATION, 2022, 28 (03) : 363 - 375
  • [42] Waitlist Survival of Patients With Primary Sclerosing Cholangitis in the Model for End-Stage Liver Disease Era
    Goldberg, David
    French, Benjamin
    Thomasson, Arwin
    Reddy, K. Rajender
    Halpern, Scott D.
    LIVER TRANSPLANTATION, 2011, 17 (11) : 1355 - 1363
  • [43] Outcomes After Liver Transplantation in Patients Achieving a Model for End-Stage Liver Disease Score of 40 or Higher
    Alexopoulos, Sophoclis
    Matsuoka, Lea
    Cho, Yong
    Thomas, Elizabeth
    Sheikh, Mohd
    Stapfer, Maria
    Dhanireddy, Kiran
    Sher, Linda
    Selby, Rick
    Genyk, Yuri
    TRANSPLANTATION, 2013, 95 (03) : 507 - 512
  • [44] UNITED KINGDOM MODEL FOR END-STAGE LIVER DISEASE AND MODEL FOR END STAGE LIVER DISEASE SCORES PREDICT OUTCOME AFTER OESOPHAGEAL VARICEAL HAEMORRHAGE
    Mangrolia, N.
    Gelson, W.
    Zissimopoulos, A.
    Lee, K.
    Allison, M.
    GUT, 2010, 59 : A104 - A104
  • [45] Predicting End-Stage Renal Disease After Liver Transplant
    Israni, A. K.
    Xiong, H.
    Liu, J.
    Salkowski, N.
    Trotter, J. F.
    Snyder, J. J.
    Kasiske, B. L.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 (07) : 1782 - 1792
  • [46] Calciphylaxis in end-stage liver and renal disease patients before and after transplant
    Couri, Thomas
    Stier, Matthew
    Mikolajczyk, Adam
    Aronsohn, Andrew
    CLINICAL TRANSPLANTATION, 2018, 32 (06)
  • [47] Stage of Cirrhosis Predicts the Risk of Liver-Related Death in Patients With Low Model for End-Stage Liver Disease Scores and Cirrhosis Awaiting Liver Transplantation
    Wedd, Joel
    Bambha, Kiran M.
    Stotts, Matt
    Laskey, Heather
    Colmenero, Jordi
    Gralla, Jane
    Biggins, Scott W.
    LIVER TRANSPLANTATION, 2014, 20 (10) : 1193 - 1201
  • [48] Mortality in patients with end-stage liver disease above model for end-stage liver disease 3.0 of 40
    Tarlow, Branden D.
    Kim, W. Ray
    Mannalithara, Ajitha
    Kwo, Paul Y.
    Bonham, C. Andrew
    Kwong, Allison
    HEPATOLOGY, 2023, 77 (03) : 851 - 861
  • [49] Living-Donor Liver Transplant for Patients With End-stage Liver Disease
    Zhang, Chengcheng
    Ou, Yanjiao
    Zhang, Leida
    JAMA SURGERY, 2023, 158 (04) : 427 - 428
  • [50] Potential indications for liver transplant in Child-Pugh A and Model for End-stage Liver Disease exception for hepatocellular carcinoma in Japan
    Goto, Ryoichi
    Shimamura, Tsuyoshi
    Nakajima, Tomoaki
    Ogawa, Koji
    Tanaka, Kazunari
    Shimizu, Takao
    Minami, Ryosuke
    Matsui, Takeshi
    Akutsu, Noriyuki
    Sasaki, Shigeru
    Kakisaka, Tatsuhiko
    Kawamura, Norio
    Watanabe, Masaaki
    Taketomi, Akinobu
    HEPATOLOGY RESEARCH, 2025,